Streetbeat News

Price Targets

QTWO

Piper Sandler analyst Arvind Ramnani upgraded Q2 Holdings (NYSE:QTWO) from Underweight to Neutral and increased the price target from $30 to $41.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:04 am

NOK

Raymond James analyst Simon Leopold has maintained an Outperform rating on Nokia (NYSE:NOK) but reduced the price target from $4.5 to $4.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:02 am

REVG

REV Group, Inc. (NYSE:REVG) is expected to report higher earnings for Q4 fiscal 2023, with analysts predicting earnings of 34 cents per share compared to 28 cents per share a year ago, and revenue of $666.13 million, up from $623.6 million. The company previously reported a 14.3% year-over-year sales growth in Q3 FY23. Analysts from Baird, BMO Capital, Goldman Sachs, and Credit Suisse have recently updated their ratings and price targets for REVG, with varying opinions on the stock's performance.

Portfolio Pulse from Avi Kapoor

December 13, 2023 | 6:50 am

SHIBUSD

Shiba Inu (CRYPTO: SHIB) has seen a 0.51% decrease in its supply on exchanges over the past month, indicating less selling pressure and potential for price gains. The Shibarium network has experienced a surge in transactions and wallet count since its launch, with a significant number of SHIB tokens burned recently. Despite these developments, SHIB's price has dropped by 2.75% in the last 24 hours.

Portfolio Pulse from Mehab Qureshi

December 13, 2023 | 5:42 am

ACHV

Achieve Life Sciences' stock price has fallen following the announcement of a potential delay in the New Drug Application filing for Cytisinicline due to FDA feedback. Additionally, Oppenheimer has reduced its price target for Achieve Life Sciences from $21 to $18.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 8:59 pm

INCY

Incyte Corporation (NASDAQ:INCY) stock has seen a significant increase, rising approximately 13% since Monday. The surge follows a period of consolidation over November and comes after the company's third-quarter financial results and 2023 net product revenue guidance. Additionally, the stock's price target has varied between $63 to $98 in the past month. The recent spike is attributed to the announcement of full results from the Phase 2 AGAVE-201 trial of axatilimab, presented at the American Society of Hematology Annual Meeting 2023. At the time of publication, INCY shares were up 8.75% at $62.03.

Portfolio Pulse from Ryan Gustafson

December 12, 2023 | 8:33 pm

MRNA

Moderna's stock price fell 5.5% to $77.51 following the announcement of changes to its operating model aimed at aligning with its business goals. Additionally, the company's Chief Commercial Officer has stepped down, and Morgan Stanley has reduced its target price for Moderna to $92.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 7:34 pm

EA

Electronic Arts (NASDAQ:EA) has received 8 analyst ratings in the last quarter, with an average 12-month price target of $149.62, a high of $162.00, and a low of $139.00. The ratings include 2 bullish, 2 somewhat bullish, and 4 indifferent. The average price target has increased by 5.61% over the past month. Analysts rate stocks based on future earnings potential and company risk profile, typically updating their ratings quarterly or after significant company events.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 7:00 pm

HPQ

HP (NYSE:HPQ) has received mixed analyst ratings in the last quarter, with 2 bullish, 2 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for HPQ among 6 analysts is $34.17, with a high of $40.00 and a low of $31.00. This target has increased by 9.34% from the previous target of $31.25. Analyst ratings are opinions on stock performance and are updated quarterly.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 7:00 pm

HUM

Over the past 3 months, 8 Wall Street analysts have published their opinions on Humana (NYSE:HUM) stock, with 7 out of 8 showing a positive stance (2 bullish, 5 somewhat bullish) and 1 indifferent. The average 12-month price target for Humana is $583.88, with a high of $599.00 and a low of $550.00, representing a slight decrease of 0.28% from the previous target of $585.50. Analysts typically review stocks quarterly or after major company updates, using financial predictions and company performance to guide their ratings.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 7:00 pm